* Ocugen Inc reported a quarterly adjusted loss of 5 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -7 cents. The mean expectation of three analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -7 cents to -6 cents per share.
* Revenue was $6.83 million; analysts expected zero.
* Ocugen Inc's reported EPS for the quarter was a loss of 5 cents.
* Ocugen Inc shares had risen by 10.4% this quarter and gained 214.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 2.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Ocugen Inc is $5.00 This summary was machine generated from LSEG data May 14 at 02:22 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.06 -0.05 Beat
Dec. 31 2023 -0.06 -0.03 Beat
Sep. 30 2023 -0.07 -0.06 Beat
Jun. 30 2023 -0.07 -0.08 Missed
Comments